RISC * CORO_12H Crosstabulation

Count

CORO_12H Total

DA NU

1 3 29 32
RISC
2 0 18 18
Total 3 47 50
Chi-Square Tests

Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)

Pearson Chi-Square 1.795a 1 .180

Continuity Correctionb .518 1 .472
Likelihood Ratio 2.784 1 .095
Fisher's Exact Test .544 .253
N of Valid Case 50

Risk Estimate

Value 95% Confidence Interval

Lower Upper

For cohort CORO_12H =

.906 .811 1.013
NU

N of Valid Cases 50
 ANALIZA STATISTICA DUPA ASOCIERE ASA+BRILIQUE SAU ASA+PLAVIX

COMPLICATII_MEDICATIEa

Frequency Percent Valid Percent Cumulative

Percent

DA 3 21.4 21.4 21.4

Valid NU 11 78.6 78.6 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
COMPLICATII_MEDICATIEa

Frequency Percent Valid Percent Cumulative

Percent

DA 4 11.1 11.1 11.1

Valid NU 32 88.9 88.9 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix

C_NSTEMIa

Frequency Percent Valid Percent Cumulative

Percent

DA 4 28.6 28.6 28.6

Valid NU 10 71.4 71.4 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
C_NSTEMIa

Frequency Percent Valid Percent Cumulative

Percent

DA 14 38.9 38.9 38.9

Valid NU 22 61.1 61.1 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix
 TIP_TERAPIEa

Frequency Percent Valid Percent Cumulative

Percent

CHIR 5 35.7 35.7 35.7

CONSERV 4 28.6 28.6 64.3

Valid
INTERV 5 35.7 35.7 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
TIP_TERAPIEa

Frequency Percent Valid Percent Cumulative

Percent

CHIR 12 33.3 33.3 33.3

CONSERV 9 25.0 25.0 58.3

Valid
INTERV 15 41.7 41.7 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix

LMa

Frequency Percent Valid Percent Cumulative

Percent

DA 3 21.4 21.4 21.4

Valid NU 11 78.6 78.6 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
LMa

Frequency Percent Valid Percent Cumulative

Percent

DA 11 30.6 30.6 30.6

Valid NU 25 69.4 69.4 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix
 INTERP_CRUSADEa

Frequency Percent Valid Percent Cumulative

Percent

FOARTE INALT 2 14.3 14.3 14.3

FOARTE SCAZUT 2 14.3 14.3 28.6

INALT 2 14.3 14.3 42.9

Valid
MODERAT 3 21.4 21.4 64.3

SCAZUT 5 35.7 35.7 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
INTERP_CRUSADEa

Frequency Percent Valid Percent Cumulative Percent

FOARTE INALT 10 27.8 27.8 27.8

FOARTE SCAZUT 6 16.7 16.7 44.4

INALT 7 19.4 19.4 63.9

Valid
MODERAT 6 16.7 16.7 80.6

SCAZUT 7 19.4 19.4 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix
LEZIUNI_COROa

Frequency Percent Valid Percent Cumulative Percent

1C 4 28.6 28.6 28.6

2C 3 21.4 21.4 50.0

Valid 3C 5 35.7 35.7 85.7

FARA 2 14.3 14.3 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
LEZIUNI_COROa

Frequency Percent Valid Percent Cumulative Percent

1C 11 30.6 30.6 30.6

2C 7 19.4 19.4 50.0

3C 14 38.9 38.9 88.9

Valid
FARA 3 8.3 8.3 97.2

REFUZ 1 2.8 2.8 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix
 ANEMIEa

Frequency Percent Valid Percent Cumulative

Percent

DA 6 42.9 42.9 42.9

Valid NU 8 57.1 57.1 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
ANEMIEa

Frequency Percent Valid Percent Cumulative

Percent

DA 13 36.1 36.1 36.1

Valid NU 23 63.9 63.9 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix
FIAa

Frequency Percent Valid Percent Cumulative

Percent

DA 1 7.1 7.1 7.1

Valid NU 13 92.9 92.9 100.0

Total 14 100.0 100.0

a. ASA_P_B = Brilique
FIAa

Frequency Percent Valid Percent Cumulative

Percent

DA 10 27.8 27.8 27.8

Valid NU 26 72.2 72.2 100.0

Total 36 100.0 100.0

a. ASA_P_B = Plavix
 ASA_P_B * C_NSTEMI Crosstabulation
Count

C_NSTEMI Total

DA NU

Brilique 4 10 14
ASA_P_B
Plavix 14 22 36
Total 18 32 50
Chi-Square Tests

Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)

Pearson Chi-Square .466a 1 .495

Continuity Correctionb .126 1 .723
Likelihood Ratio .476 1 .490
Fisher's Exact Test .744 .367
N of Valid Cases 50

OR= 0,629

ASA_P_B * COMPLICATII_MEDICATIE Crosstabulation

Count

COMPLICATII_MEDICATIE Total

DA NU

Brilique 3 11 14
ASA_P_B
Plavix 4 32 36
Total 7 43 50
Chi-Square Tests

Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)

Pearson Chi-Square .891a 1 .345

Continuity Correctionb .240 1 .624
Likelihood Ratio .832 1 .362
Fisher's Exact Test .384 .300
N of Valid Cases 50
 ASA_P_B * ANEMIE Crosstabulation
Count

ANEMIE Total

DA NU

Brilique 6 8 14
ASA_P_B
Plavix 13 23 36
Total 19 31 50
Chi-Square Tests

Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)

Pearson Chi-Square .195a 1 .659

Continuity Correctionb .014 1 .907
Likelihood Ratio .193 1 .660
Fisher's Exact Test .750 .449
N of Valid Cases 50

ASA_P_B * FUMATOR Crosstabulation

Count

FUMATOR Total

DA NU

Brilique 5 9 14
ASA_P_B
Plavix 10 26 36
Total 15 35 50
 Chi-Square Tests

Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)

Pearson Chi-Square .302a 1 .582

Continuity Correctionb .043 1 .837
Likelihood Ratio .297 1 .586
Fisher's Exact Test .733 .411
N of Valid Cases 50

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.20.
b. Computed only for a 2x2 table